Company PolyPid Ltd.

PYPD

IL0011326795

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:30:00 2024-04-26 EDT			5-day change	1st Jan Change
4.752 ^USD	-1.12%		+8.01%	+25.07%

02-14	Transcript : PolyPid Ltd., Q4 2023 Earnings Call, Feb 14, 2024
02-14	PolyPid Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Number of employees: 61

Managers	Title	Age	Since
Dikla Akselbrad CEO	Chief Executive Officer	50	14-06-30
Jonny Missulawin DFI	Director of Finance/CFO	37	-
Olga Belotserkovsky CTO	Chief Tech/Sci/R&D Officer	-	16-02-29
Ori Warshavsky COO	Chief Operating Officer	46	-
Dalit Hazan CTO	Chief Tech/Sci/R&D Officer	53	16-03-31
Anthony J. Senagore CTO	Chief Tech/Sci/R&D Officer	-	21-07-11
Tal Vilnai LAW	General Counsel	-	23-08-31
Orna Blum LAW	General Counsel	-	16-02-29
Jean-Marc Hagai PRN	Corporate Officer/Principal	-	-
Rivi Lev-ari HRO	Human Resources Officer	-	-

Members of the board	Title	Age	Since
Robert Stein BRD	Director/Board Member	73	20-02-29
Itzhak Krinsky BRD	Director/Board Member	71	18-11-30
Yechezkel Barenholz BRD	Director/Board Member	82	08-03-31
Dikla Akselbrad CEO	Chief Executive Officer	50	14-06-30
Jacob Harel CHM	Chairman	68	17-12-13
Nir Dror BRD	Director/Board Member	47	20-04-30
Nurit Tweezer-Zaks BRD	Director/Board Member	58	11-05
Yossi BenAmram		-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	4,797,252	3,354,266 ( 69.92 %)	0	69.92 %

Name	Equities	%	Valuation
Aurum Ventures MKI Ltd. 16.28 %	781,152	16.28 %	4 M $
Yehuda Nir 10.40 %	499,101	10.40 %	2 M $
AIGH Capital Management LLC 9.990 %	479,246	9.990 %	2 M $
Rosalind Advisors, Inc. 8.667 %	415,800	8.667 %	2 M $
Xenia Venture Capital Ltd. (Direct Investments) 8.564 %	410,826	8.564 %	2 M $
Lukach Aharon 5.496 %	263,638	5.496 %	1 M $
The Hewlett Fund LP 5.200 %	249,480	5.200 %	1 M $
DAFNA Capital Management LLC 4.334 %	207,900	4.334 %	956 340 $
Rosalind Advisors, Inc. 0.8667 %	41,580	0.8667 %	191 268 $
Shavit Capital Management 0.3112 %	14,930	0.3112 %	68 678 $

PolyPid Ltd.

18 Hasivim Street

495376, Petach Tikva

http://www.polypid.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.752 USD

Average target price

12.33 USD

Spread / Average Target

+159.51%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
POLYPID LTD.	+25.07%	22.8M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals